UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential
Credit Suisse initiated coverage on XOMA Corporation (NASDAQ: XOMA) with an Outperform rating and a $4 price target.
Credit Suisse commented, "Xoma has recently refocused its efforts and bolstered its balance sheet to advance the development of gevokizumab for multiple indications. Retained marketing rights, a well-designed clinical program, and multiple data readouts in the next 12 months provide for upside potential, although with speculative risk."
XOMA Corporation closed at $2.67 on Monday.
Latest Ratings for XOMA
|Apr 2014||McNicoll Lewis Vlak||Upgrades||Hold||Buy|
|Mar 2014||McNicoll Lewis Valk||Downgrades||Buy||Hold|
|Mar 2014||Credit Suisse||Downgrades||Outperform||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.